Oxford and GSK launch £50m programme to advance cancer research
Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.
Read moreLatest News
Upcoming Talks
Prof Beth Psaila - Exploring the MEGAverse - new insights into megakaryocytes and platelets, and their roles in cancer
Wednesday, 15 July 2026, 12.30pm to 1.30pm
Modulating, Not Depleting: Engineered Bacteria for the Collagen Barrier in Solid Tumors
Thursday, 16 July 2026, 12.15pm to 1.15pm
3’ RNA Uridylation: Biological Insights and Targeted Inhibition as a Cancer Therapy
Thursday, 16 July 2026, 3pm to 4pm
Genetic and Epigenetic Regulation of Synovial Fibroblasts in Rheumatoid Arthritis
Monday, 20 July 2026, 12pm to 1pm
Managing Metabolic Disease in Mothers: Mechanisms and Interventions to Improve Fetal Health
Monday, 20 July 2026, 2pm to 3pm
Latest publications
The double-edged nature of antibody bivalency: mathematical and experimental analysis of cell surface antigen occupancy and opsonization.
Journal article
Heirene L. et al, (2026), MAbs, 18
DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models.
Journal article
Morgado-Cáceres P. et al, (2026), Oncoimmunology, 15
Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization.
Journal article
van Niekerk L. et al, (2026), MAbs, 18
Systematic review and data-driven insights into CHO cell engineering for next-generation antibody production.
Journal article
Schulz A. et al, (2026), MAbs, 18